Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review

Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs designed to exploit synthetic lethality, and were first introduced as a cancer-targeting strategy in 2005. They have led to a major change in the treatment of advanced ovarian cancer, and altered the natural histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Boussios, Stergios, Karihtala, Peeter, Moschetta, Michele, Karathanasi, Afroditi, Sadauskaite, Agne, Rassy, Elie, Pavlidis, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787707/
https://www.ncbi.nlm.nih.gov/pubmed/31374917
http://dx.doi.org/10.3390/diagnostics9030087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787707/
https://www.ncbi.nlm.nih.gov/pubmed/31374917
http://dx.doi.org/10.3390/diagnostics9030087

Ejemplares similares